Abstract:Introduction: Bioresorbable scaffolds (BRS) have been developed to overcome limitations related to late stent failures of drug-eluting-stents, but previous studies have observed lumen reduction over time after implantation of BRS. The aim of the study was to investigate if lesion preparation with a scoring balloon compared to a standard non-compliant balloon minimizes lumen reduction after implantation of a Magmaris BRS (MgBRS) assessed with optical coherence tomography (OCT) and intravascular ultrasound (IVUS). Method: Eighty-two patients with stable angina pectoris were included and randomized in a ratio 1:1 to lesion preparation with either a scoring balloon or a standard non-compliant balloon prior to implantation of a MgBRS. The primary endpoint was minimal lumen area (MLA) 6 months after MgBRS implantation. Results: Following MgBRS implantation, MLA (6.4 ± 1.6 mm2 vs. 6.3 ± 1.5 mm2, p=0.65), mean scaffold area (7.8 ± 1.5 mm2 vs. 7.5 ± 1.7 mm2, p=0.37), and mean lumen area (8.0 ± 1.6 mm2 vs. 7.7 ± 2.1 mm2, p=0.41) did not differ significantly in patients where the lesions were prepared with scoring vs. standard non-compliant balloon respectively. Six-month angiographic follow-up with OCT and IVUS was available in seventy-four patients. The primary endpoint, 6-months MLA, was significantly larger in lesions prepared with a scoring balloon compared to a standard non-compliant balloon (4.7 ± 1.4 mm2 vs. 3.9 ± 1.9 mm2, p=0.04), whereas mean lumen area (7.2 ± 1.4 mm3 vs. 6.8 ± 2.2, p=0.35) did not differ significantly. IVUS findings showed no difference in mean vessel area at the lesion site from baseline to follow-up in the scoring balloon group (16.8 ± 2.9 mm2 vs. 17.0 ± 3.6 mm2, p=0.62), whereas mean vessel area (17.1 ± 4.4 mm2 vs. 15.7 ± 4.9 mm2, p<0.001) was smaller in lesions prepared with a standard non-compliant balloon due to negative remodeling. Conclusion: Lesion preparation with a scoring balloon prior to implantation of a MgBRS resulted in significantly larger MLA after 6 months due to less negative remodeling compared to lesion preparation with a standard non-compliant balloon. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: .

One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI registry)

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Thirty-Day and One-Year Clinical Outcomes of Bioresorbable Vascular Scaffold Implantation: A Single-Center Experience

Clinical Outcomes Prior to and Following Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.

5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry

Long-term outcomes following bioresorbable vascular scaffolds

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffold for cardiac allograft vasculopathy (CART)

Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials

Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study

The Absorb GT1 Bioresorbable Vascular Scaffold System - 5-Year Post-Market Surveillance Study in Japan

One-year Clinical Outcomes and Multislice Computed Tomography Angiographic Results Following Implantation of the NeoVas Bioresorbable Sirolimus-Eluting Scaffold in Patients with Single De Novo Coronary Artery Lesions

Optimal Pre-dilatation Treatment before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis. The OPTIMIS trial

Mid-to-long term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in coronary artery diseases: a meta-analysis of 7321 patients

Efficacy and safety of bioresorbable scaffolds in patients with coronary bifurcation lesions: A systematic review and meta-analysis

Final Report of the 5-Year Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in the Treatment of Single De Novo Coronary Lesions in a First-in-human Study

Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China Trial.

Preliminary Clinical and Radiologic Outcome of Matched Patients with Thoracoabdominal Aortic Aneurysms Treated by Low-Profile vs Standard Profile Branched Aortic Endografts

Evaluation of potential substrates for restenosis and thrombosis in overlapped versus edge-to-edge juxtaposed bioabsorbable scaffolds: Insights from a computed fluid dynamic study

Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions

Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy